Companies · Other Health Care

Abcam plc

CAMBRIDGE · Other Health Care

Diligence memoA one-page analyst read on Abcam plc — recommendation, valuation, rhythm, risks.
$79.6M
Total raised · real
3
Rounds
0.0×
Latest step-up
Top 6%
Sector rank · raised
Series C
Latest stage · inferred · Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Abcam plc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.02× the median modeled value of Series C Other Health Care companies in 2019–2021 (46 peers) — value vs value, same stage and era.
  • Issuer reports $100M+ revenue while modeled below niche peers.
Dormant
  • Last raise 6.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Abcam plc is one of 5376 Other Health Care companies tracked from CAMBRIDGE. By capital raised it ranks among the largest (ahead of 95% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$100M+
Issuer revenue
Rule 506(b)
Reg D exemption
3
Investors (latest)
2020-03-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeed · 2011-05-23 Raised $1.8M (real) Modeled valuation $45M (est)$1.8M$45MSeed2011Series C · 2012-04-19 Raised $77M (real) Modeled valuation $1.8B (est)$77M$1.8BSeries C2012Series C · 2020-03-03 Raised $800K (real) Modeled valuation $18M (est)$800K$18MSeries C2020+$77M+$800KCumulative $80M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.8M · 2011
Series C$77.0M · 2012no Series A / Series B on file
Series C extension$800K · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$18.3M
Base estimate est.
$2.9M
Conservative case
$48.2M
Upside case
$5.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $44.6M · 2011-05-232011Series C · modeled $1.8B · 2012-04-19Series C · modeled $18.3M · 2020-03-032020
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
6.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
53 mo
Avg between rounds
$9.1M/yr
Capital velocity
15.1 yr
On record since
2011
First round
3
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 33× above median
This company$79.6M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$800K
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 0.8× of median
This company$18.3M
Sector median$22.1M

Raised more than 95% of sector peers (real $). Modeled value above 46% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #46 of 46.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Avail Medsystems, Inc. · Series C Raised $126.7M · modeled $2.2B (est)Whoop, Inc. · Series C Raised $180.4M · modeled $2.1B (est)HRGi Holdings, Inc. · Series C Raised $91.2M · modeled $2.1B (est)Ambulnz, Inc. · Series C Raised $90.0M · modeled $2.1B (est)MedAvail, Inc. · Series C Raised $97.0M · modeled $2.0B (est)SOC Telemed, Inc. · Series C Raised $103.0M · modeled $1.9B (est)Eargo, Inc. · Series C Raised $187.4M · modeled $1.8B (est)Truth Holdings, L.P. · Series C Raised $88.8M · modeled $1.6B (est)NeuroPace Inc · Series C Raised $208.6M · modeled $1.5B (est)DermTech, Inc. · Series C Raised $98.9M · modeled $1.5B (est)Mydna, Inc · Series C Raised $72.1M · modeled $1.4B (est)Ancora Heart, Inc. · Series C Raised $151.3M · modeled $1.4B (est)Abcam plc (this company) Raised $79.6M · modeled $18.3M (est)Abcam plc
CompanyStageRaised · realValue · estvs peer med.
Avail Medsystems, Inc.Series C$126.7M$2.2B1.87×
Whoop, Inc.Series C$180.4M$2.1B1.81×
HRGi Holdings, Inc.Series C$91.2M$2.1B1.81×
Ambulnz, Inc.Series C$90.0M$2.1B1.79×
MedAvail, Inc.Series C$97.0M$2.0B1.75×
SOC Telemed, Inc.Series C$103.0M$1.9B1.65×
Eargo, Inc.Series C$187.4M$1.8B1.61×
Truth Holdings, L.P.Series C$88.8M$1.6B1.43×
NeuroPace IncSeries C$208.6M$1.5B1.33×
DermTech, Inc.Series C$98.9M$1.5B1.29×
Mydna, IncSeries C$72.1M$1.4B1.26×
Ancora Heart, Inc.Series C$151.3M$1.4B1.24×
Abcam plc this companySeries C$79.6M$18.3M0.02×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.8M2011-05-23$9.0M$44.6M85%
Series C$77.0M2012-04-19$513.3M$1.8B85%
Series C$800K2020-03-03$5.3M$18.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.8M2011-05-23
    • First recorded raise — entered as Seed.
    • 3 investors on this round.
  2. Series C$77.0M2012-04-19
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 42.8× larger than the prior — scaling up.
    • 118 investors on this round.
  3. Series C$800K2020-03-03
    • Raised again after 94 mo — slower than the ~14 mo sector norm.
    • Round 96.2× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 3 investors on this round.
Intelligence
2024 ~Q3
Modeled next raise · ~53mo cadence
$800K
Modeled next size est.range $800K$1.3M
0.0×
Last step-up
$9.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael Ross17 other2012-04
Peter Keen1 other2012-04
Alan Thomas Hirzel2020-03
Anthony Martin2012-04
David James Warwick2011-05
Giles Francis Bertram Kerr2020-03
Jeff Iliffe2011-05
Jeff Iliffee2012-04
Jim Warwick2012-04
Jonathan Milner2011-05
Jonathan Simon Milner2020-03
Louise Alexandra Virginia Charlotte Patten2020-03
Mara Glickman Aspinall2020-03
Mark James Webster2011-05
Michael Redmond2011-05
Michael Shaun Baldock2020-03
Mike Redmond2012-04
Murray Hennessy2012-04
Peter James Keen2011-05
Peter Vance Allen2020-03
Tim James Dye2011-05
Tony James Kouzarides2011-05
Tony Kouzarides2012-04
Registry & provenance

Abcam plc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1492074
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Therini Bio, Inc.BiotechnologySeries C$84.2M$1.1Bnetwork1 shared operator · same stage
Xilio Therapeutics, Inc.BiotechnologySeries C$145.2M$3.0Bnetwork1 shared operator · same stage
TRex Holdings Inc.BiotechnologySeries C$42.3M$329.3Mnetwork1 shared operator · same stage
X4 Pharmaceuticals, IncBiotechnologySeries C$320.3M$494.8Mnetwork1 shared operator · same stage
Carrot Inc.Other Health CareSeries B$51.0M$20.8Msame sector
Link Medicine CorpBiotechnologySeries B$64.8M$190.8Mnetwork1 shared operator
IDev Technologies IncOther Health CareSeries B$44.2M$18.4Msame sector
Cervel Neurotech, Inc.Other Health CareSeries A$37.2M$20.2Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Mdp Acm Holdings, LlcOther Health CareSeries C$1.4B85%
Brogent China Life Sciences Ltd.Other Health CareSeed$37.2M81%
PLM Management Holding Group, LLCOther Health CareSeed$21.4M81%
LiveCare Corp.Other Health CareSeed$33.5M80%
Brogent International LLCOther Health CarePre-Seed$30.8M80%
BXNG Holdings LLCOther Health CarePre-Seed$460K80%
Alveo Investments, LLCOther Health CareSeed$13.0M80%
FPPS Holdings, LLCOther Health CareSeries A$7.2M80%
Frequently asked
How much funding has Abcam plc raised?
Abcam plc has raised approximately $79.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Abcam plc's estimated valuation?
Provath's modeled valuation for Abcam plc is approximately $18.3M (modeled range $2.9M–$48.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Abcam plc at?
Abcam plc's latest modeled financing stage is Series C. Its most recent recorded round closed around Tue Mar 03.
What does Abcam plc do and where is it based?
Abcam plc operates in the Other Health Care sector, based in CAMBRIDGE.
Explore related

See where Abcam plc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Abcam plc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.